Market Cap 1.11B
Revenue (ttm) 291.85M
Net Income (ttm) 550,000.00
EPS (ttm) N/A
PE Ratio 104.33
Forward PE 52.17
Profit Margin 0.19%
Debt to Equity Ratio 17.00
Volume 1,492,100
Avg Vol 1,734,666
Day's Range N/A - N/A
Shares Out 172.64M
Stochastic %K 31%
Beta 0.85
Analysts Strong Sell
Price Target $11.14

Company Profile

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatmen...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 844 445 5704
Address:
1375 West Fulton Street, Suite 1300, Chicago, United States
stockpimpbot5000
stockpimpbot5000 May. 15 at 3:39 AM
$XERS Up BIG in the after market hours? Let me order my Ferrari now. 😂
0 · Reply
undefeatedchamp
undefeatedchamp May. 15 at 12:14 AM
0 · Reply
undefeatedchamp
undefeatedchamp May. 15 at 12:14 AM
$XERS @Fujidepro @TymeTryethTroth
1 · Reply
meistermell
meistermell May. 14 at 5:05 PM
$XERS headed towards $7
0 · Reply
undefeatedchamp
undefeatedchamp May. 14 at 4:23 PM
$XERS @Fujidepro A very quick glance at the chart and here's what I see: Short term - neutral, there is slight bearish divergence Next few weeks - I look at last week as a pivot week; the weekly candle shows what could be a temporary top; if a bearish move were to hit my guess is that it comes next week or the week after. A bullish move would be confirmed with 2 weekly closes above last week's high. Also watch how price reacts to the 20 DMA in the upcoming weeks as it has bounced or hugged the line then come back up each time. A break below means a drop down is coming. Longs want to see a monthly close $6.13 to have 2 consecutive green monthly candles. Also want to hold above the April low of $5.76. Any breach of that and price can drop to the low 5's again fast. My own personal forecast back a couple of months ago was that we would see low 5's, maybe even high 4's. That was based on that large W I had a macro level. My target month was June or July. Still in the realm of possibility.
2 · Reply
GuiltyAsCharged
GuiltyAsCharged May. 14 at 3:49 PM
$XERS One step forward, two steps back until sub $6. Then buy back in...
0 · Reply
Struin
Struin May. 14 at 2:56 PM
$XERS My favorites this year Xeris and Onward Medical
0 · Reply
Alon_R
Alon_R May. 14 at 2:34 PM
EOY 2026 ER (estimated timeline) In my view, reality will not be able to ignore the exponential RECORLEV trend for much longer. The Massive revenue growth, should lead to strong EBITDA and EPS improvement(strong earnings), alongside the advancement of XP-8121 (Mega Blockbuster candidate). When it goes👆, it goes(as we all know) & actual + forward looking data strongly supporting that likelihood.
0 · Reply
Fujidepro
Fujidepro May. 14 at 11:22 AM
$XERS Barclays reiterated $9 and a buy rating https://www.tipranks.com/news/blurbs/xeris-pharmaceuticals-xers-receives-a-buy-from-barclays-blurbs-news?utm_source=webullapp.com&utm_medium=referral
0 · Reply
Bullisch_150
Bullisch_150 May. 14 at 10:53 AM
$XERS big money for deal incoming
0 · Reply
Latest News on XERS
Xeris Biopharma Holdings Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 7 days ago

Xeris Biopharma Holdings Earnings Call Transcript: Q1 2026


Xeris Biopharma Reports First Quarter 2026 Financial Results

May 7, 2026, 7:00 AM EDT - 7 days ago

Xeris Biopharma Reports First Quarter 2026 Financial Results


Xeris Biopharma Holdings Earnings Call Transcript: Q4 2025

Mar 2, 2026, 8:30 AM EST - 2 months ago

Xeris Biopharma Holdings Earnings Call Transcript: Q4 2025


Xeris Biopharma initiated with an Overweight at Barclays

2025-12-08T21:30:17.000Z - 5 months ago

Xeris Biopharma initiated with an Overweight at Barclays


Xeris Biopharma Holdings Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 6 months ago

Xeris Biopharma Holdings Earnings Call Transcript: Q3 2025


Xeris Biopharma assumed with a Buy at H.C. Wainwright

2025-08-12T10:10:13.000Z - 9 months ago

Xeris Biopharma assumed with a Buy at H.C. Wainwright


Xeris Biopharma Holdings Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 10 months ago

Xeris Biopharma Holdings Earnings Call Transcript: Q2 2025


Xeris Biopharma Holdings Transcript: Investor Day 2025

Jun 3, 2025, 10:00 AM EDT - 1 year ago

Xeris Biopharma Holdings Transcript: Investor Day 2025


Xeris Announces Details for Analyst & Investor Day

May 20, 2025, 7:30 AM EDT - 1 year ago

Xeris Announces Details for Analyst & Investor Day


Xeris Biopharma Holdings Earnings Call Transcript: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Xeris Biopharma Holdings Earnings Call Transcript: Q1 2025


Xeris Announces Changes to Its Board of Directors

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Xeris Announces Changes to Its Board of Directors


Xeris Biopharma price target raised to $6 from $5 at Leerink

2025-03-07T22:05:42.000Z - 1 year ago

Xeris Biopharma price target raised to $6 from $5 at Leerink


Xeris Biopharma Holdings Earnings Call Transcript: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Xeris Biopharma Holdings Earnings Call Transcript: Q4 2024


Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

Feb 24, 2025, 8:00 AM EST - 1 year ago

Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer


Xeris to Participate in Upcoming Investor Conferences

Feb 5, 2025, 8:00 AM EST - 1 year ago

Xeris to Participate in Upcoming Investor Conferences


Xeris Expects to Exceed Full-Year 2024 Financial Guidance

Jan 10, 2025, 7:00 AM EST - 1 year ago

Xeris Expects to Exceed Full-Year 2024 Financial Guidance


Xeris Biopharma Holdings Earnings Call Transcript: Q3 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Xeris Biopharma Holdings Earnings Call Transcript: Q3 2024


Xeris Biopharma Reports Third Quarter 2024 Financial Results

Nov 8, 2024, 7:00 AM EST - 1 year ago

Xeris Biopharma Reports Third Quarter 2024 Financial Results


Xeris Biopharma Holdings Earnings Call Transcript: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Xeris Biopharma Holdings Earnings Call Transcript: Q2 2024


Xeris Biopharma Announces CEO Succession Plan

Jul 8, 2024, 7:00 AM EDT - 2 years ago

Xeris Biopharma Announces CEO Succession Plan


Xeris Biopharma Holdings Earnings Call Transcript: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Xeris Biopharma Holdings Earnings Call Transcript: Q1 2024


Xeris Biopharma Holdings Earnings Call Transcript: Q4 2023

Mar 6, 2024, 8:30 AM EST - 2 years ago

Xeris Biopharma Holdings Earnings Call Transcript: Q4 2023


Xeris Biopharma Updates Its Outlook for 2023

Jan 4, 2024, 7:00 AM EST - 2 years ago

Xeris Biopharma Updates Its Outlook for 2023


Xeris Biopharma Holdings Earnings Call Transcript: Q3 2023

Nov 9, 2023, 8:30 AM EST - 2 years ago

Xeris Biopharma Holdings Earnings Call Transcript: Q3 2023


Xeris Biopharma Reports Third Quarter 2023 Financial Results

Nov 9, 2023, 7:00 AM EST - 2 years ago

Xeris Biopharma Reports Third Quarter 2023 Financial Results


stockpimpbot5000
stockpimpbot5000 May. 15 at 3:39 AM
$XERS Up BIG in the after market hours? Let me order my Ferrari now. 😂
0 · Reply
undefeatedchamp
undefeatedchamp May. 15 at 12:14 AM
0 · Reply
undefeatedchamp
undefeatedchamp May. 15 at 12:14 AM
$XERS @Fujidepro @TymeTryethTroth
1 · Reply
meistermell
meistermell May. 14 at 5:05 PM
$XERS headed towards $7
0 · Reply
undefeatedchamp
undefeatedchamp May. 14 at 4:23 PM
$XERS @Fujidepro A very quick glance at the chart and here's what I see: Short term - neutral, there is slight bearish divergence Next few weeks - I look at last week as a pivot week; the weekly candle shows what could be a temporary top; if a bearish move were to hit my guess is that it comes next week or the week after. A bullish move would be confirmed with 2 weekly closes above last week's high. Also watch how price reacts to the 20 DMA in the upcoming weeks as it has bounced or hugged the line then come back up each time. A break below means a drop down is coming. Longs want to see a monthly close $6.13 to have 2 consecutive green monthly candles. Also want to hold above the April low of $5.76. Any breach of that and price can drop to the low 5's again fast. My own personal forecast back a couple of months ago was that we would see low 5's, maybe even high 4's. That was based on that large W I had a macro level. My target month was June or July. Still in the realm of possibility.
2 · Reply
GuiltyAsCharged
GuiltyAsCharged May. 14 at 3:49 PM
$XERS One step forward, two steps back until sub $6. Then buy back in...
0 · Reply
Struin
Struin May. 14 at 2:56 PM
$XERS My favorites this year Xeris and Onward Medical
0 · Reply
Alon_R
Alon_R May. 14 at 2:34 PM
EOY 2026 ER (estimated timeline) In my view, reality will not be able to ignore the exponential RECORLEV trend for much longer. The Massive revenue growth, should lead to strong EBITDA and EPS improvement(strong earnings), alongside the advancement of XP-8121 (Mega Blockbuster candidate). When it goes👆, it goes(as we all know) & actual + forward looking data strongly supporting that likelihood.
0 · Reply
Fujidepro
Fujidepro May. 14 at 11:22 AM
$XERS Barclays reiterated $9 and a buy rating https://www.tipranks.com/news/blurbs/xeris-pharmaceuticals-xers-receives-a-buy-from-barclays-blurbs-news?utm_source=webullapp.com&utm_medium=referral
0 · Reply
Bullisch_150
Bullisch_150 May. 14 at 10:53 AM
$XERS big money for deal incoming
0 · Reply
meistermell
meistermell May. 13 at 7:21 PM
$XERS solid day, as expected bounced hard off 6
0 · Reply
JimPee
JimPee May. 13 at 6:53 PM
$XERS does anyone understand the situation with BAQSIMI? BAQSIMI revenue declined 15% despite an 8% increase in unit volume, primarily due to higher rebates and potential duplicate 340B pharmacy discounts. BAQSIMI revenue growth expectations have been revised to flat or up low single-digits for 2026 due to ongoing pricing dynamics. Management expects to begin withdrawing BAQSIMI from a handful of non-core international markets starting in July to optimize the portfolio, while remaining in most foreign countries and all top-selling markets. They did sell more in Q1 because of discounts?
1 · Reply
Alon_R
Alon_R May. 13 at 6:05 PM
$XERS Exponential Recorlev growth ✔️ Expected ~$400M revenue by eoy 2026 (~100% revenue Growth within 2 years)✔️ 87% excellent margins ✔️ Profitable & QoQ growing eps expected ✔️ XP-8121-> Second Mega Blockbuster potential(Sole SubQ Levothyroxine option)should begin phase 3 ✔️ 👉That's easily may worth ~$3-5B Market Cap (very possible till Q4 review), based of course on fulfilling this trajectory along 2026. And growing from there.
0 · Reply
meistermell
meistermell May. 13 at 5:12 PM
$ESPR $GERN and $XERS two recommendations on our end for those looking for what could be next. And $SLS
2 · Reply
simonig1
simonig1 May. 13 at 2:10 PM
$XERS The chart below shows the indicators I use to follow stocks generally even though I am an investor and not a trader. The way I read this chart is that we bounced off the Green Support Line and our high today is higher than yesterday's high giving us a Buy signal when you also note that the RSI is above 50 and the On Balance volume is steadily increasing. Enjoy!!!
2 · Reply
GuiltyAsCharged
GuiltyAsCharged May. 13 at 1:42 PM
$XERS Guessing this gets walked back below $6 again, buy back in, and then exit by next earnings. Wash, rinse, repeat.
0 · Reply
Bullisch_150
Bullisch_150 May. 13 at 10:39 AM
$XERS deal incoming in June
0 · Reply
Invest2live
Invest2live May. 13 at 12:26 AM
$LCTX $SKYT $XERS $SKYT 210% already; congrats 🔆🌿🌟 Checkout $GAU and $RXRX; both have similar potential
0 · Reply
LurkerIndustrial1106
LurkerIndustrial1106 May. 12 at 11:03 PM
$XERS sell the company please
0 · Reply
Alon_R
Alon_R May. 12 at 2:44 PM
$XERS This is the RECORLEV graph. What you are seeing here is a clear exponential growth trajectory. Unlike many cases across the biotech sector, where growth tends to moderate in Q1, RECORLEV's momentum remained exceptionally strong. The most remarkable takeaway is the following-> "Management stated during Q1 2026 that they expect even stronger RECORLEV growth going forward, supported by record referrals, record new patient starts, and the recent commercial expansion." I have nothing further to add to that.
1 · Reply
DeadManJoaquin
DeadManJoaquin May. 12 at 2:22 PM
$XERS in for 10k shares. Bargain
0 · Reply
Mendryl
Mendryl May. 12 at 2:18 PM
$XERS halo doing well today. they could offer .2-.3 shares per xers and likely take us out.
2 · Reply